FT : EVs to start paying London congestion charge next year

EVs to start paying London congestion charge next year
TfL says changes needed to ensure scheme remains effective at managing traffic

The congestion charge in central London will rise to £18 next year as part of an overhaul by mayor Sir Sadiq Khan that includes electric vehicles paying the fee for the first time.

The current daily rate of £15, which has not been raised since 2020, will increase on January 2, then continue to climb in line with Tube fares or inflation, Transport for London announced on Thursday. 

The aim is to prevent public transport becoming relatively more expensive and to avoid incentivising people back into personal vehicles. 

EVs have until now been exempt from the charge, but will have to pay 75 per cent of the full amount starting next year, rising to 87.5 per cent from March 2030.

But motorists will only receive the discount if they sign up for the “auto-pay” service that automatically deducts funds from their bank account. 

Electric vans or battery-powered delivery vehicles that register for daily payment will receive a 50 per cent discount. 

AA president Edmund King called the EV decision a “backwards step”. He said: “Many drivers are not quite ready to make the switch to electric vehicles, so incentives are still needed to help them over the line. The mayor needs to reconsider to continue to help more essential van and car journeys in the capital go electric.”

TfL said the changes were needed to ensure the scheme “remains effective at managing traffic and congestion within central London”. 

Khan said: “While the congestion charge has been a huge success since its introduction, we must ensure it stays fit for purpose, and sticking to the status quo would see around 2,200 more vehicles using the congestion charging zone on an average weekday next year.”

The congestion charge was introduced in 2003, with a daily rate of £5, reaching £15 by 2020. 

Some 40,000 motorists pay the charge each day, while anyone driving in London with an older petrol or diesel car also faces the capital’s ultra-low emission zone (Ulez) charge, which is £12.50 a day. 

The number of EVs registered in the capital since 2019 has risen sixfold to 116,000, accounting for around a fifth of the vehicles on the road.

Under the changes, residents in the Ulez area will still be entitled to a 90 per cent discount, while EVs that are part of a car-sharing club will receive a full 100 per cent discount, in a move to try and reduce ownership. Low-income or disabled residents will receive a full discount. 

WSJ : The AI Coding Startup Favored by Tech CEOs Is Now Worth $29.3 Billion

The AI Coding Startup Favored by Tech CEOs Is Now Worth $29.3 Billion
Cursor, which was founded by four MIT graduates who are still in their mid-20s, raised $2.3 billion in its third funding round this year

  • Cursor, an AI coding tool startup, raised $2.3 billion at a $29.3 billion valuation, nearly 12 times its January level.
  • Google and Nvidia invested in Cursor’s latest funding round, deepening their existing partnerships.
  • Cursor plans to use the new capital for technical research and to invest in its new AI model, Composer.

Cursor, a startup that makes an AI coding tool beloved by engineers, has raised $2.3 billion at a $29.3 billion valuation—nearly 12 times the value the company had in January.

Accel, which invested in Cursor’s last funding round, co-led this one with Coatue, a new investor. Existing investors such as Thrive Capital and DST Global also participated in this funding round, the company’s third this year.

Other new investors include Alphabet’s GOOGL -1.58%decrease; red down pointing triangle Google and Nvidia NVDA 0.33%increase; green up pointing triangle, which Cursor invited to the round “to deepen the partnership,” said Michael Truell, co-founder and chief executive officer of the startup, in an interview.

Google provides artificial-intelligence services and cloud computing to the startup, while Nvidia is an enterprise customer. Nvidia CEO Jensen Huang has given high praise to the startup in recent public appearances.

It has rebuffed acquisition interest from a number of major AI companies, according to people familiar with the matter.

Co-founded by four Massachusetts Institute of Technology graduates who are all still in their mid-20s, the company makes an AI tool that learns a developer’s coding style to help autocomplete, edit and review lines of code, according to software engineers. The tool, which launched in 2023, has earned a cult following from professional engineers and top CEOs, from Nvidia’s Huang to Stripe’s Patrick Collison.

“One of my first interactions with Michael, he talked about being low-hype and high-pragmatism,” said Miles Grimshaw, a partner at Thrive Capital. “Which is to say, they want to focus on the work and not the hoopla.”

Cursor’s tool allows users to toggle between different AI models, from OpenAI to Anthropic to Google and more. Developers love its usability and flexibility, but the startup pays the big AI-model companies substantial fees for access to their models. The competitive pressure ratcheted up this year when OpenAI and Anthropic launched their own AI-coding tools.

In late October, the company launched its new AI model, called Composer. The model could eventually become an opportunity for the company to reduce its dependency on third-party models and keep more of its revenue, but for now the main goal is simply to continue adding more users to its product, investors said.

As the biggest AI-model builders continue to grow—in size and in product development—investors and founders are looking to Cursor to see if a startup can successfully build an independent company on top of the models from OpenAI, Anthropic and others.

“We’re excited to be one of the first examples of a large company built on their platforms,” said Truell. He added that the relationships between Cursor and the AI-model companies is simpatico. “All of the AI labs are important partners to us,” he said.

The company intends to use the new capital for technical research and to invest in Composer. “It does take significant resources, both specialized talent and also GPUs, to do something at Composer’s scale,” said Truell, referring to graphics processing units. “This funding lets us do it in a big way.”

>>> Nokia: Directed share issuance to NVIDIA completed – a change in the total

Nokia: Directed share issuance to NVIDIA completed – a change in the total number of Nokia shares (7.02)
  • Following the completion of the directed share issuance to NVIDIA (NVDA), announced by Nokia (NOK) on 28 October 2025, a total of 166 389 351 new Nokia shares were today registered with the Finnish Trade Register and entered in the book-entry system maintained by Euroclear Finland Ltd. The new shares are further delivered to NVIDIA in the form of American Depositary Shares.
  • The total number of Nokia shares following the completion of the share issuance and the registration of the new shares is 5 742 239 696. The new shares represent approximately 2.90% of the total number of Nokia shares.
  • The new shares are expected to commence trading on Nasdaq Helsinki on or about 14 November 2025, together with other Nokia shares. The new shares will not be listed on Euronext Paris, subject to the completion of the delisting process initially announced on 4 November 2025.

>>> Europe : Brokers Upgrades & Downgrades - 13th of November 2025 V3(++)

>>> Up
* ABN Amro GDRs PT Raised to 34 euros from 29 euros at RBC
* ABN Amro GDRs PT Raised to 34 euros from 29 euros at RBC
* Alcon AG Raised to Buy at Nephron Research
* Equinor Raised to Buy at SB1 Markets; PT 280 kroner
* Fincantieri Raised to Buy at Banca Akros (++)
* FinecoBank PT Raised to 25.50 euros from 17 euros at Berenberg
* Givaudan Raised to Overweight at Barclays; PT 3,900 Swiss francs
* Kuehne + Nagel Raised to Equal-Weight at Morgan Stanley
* Matvareexpressen Raised to Hold at Norne Securities
* Torm Raised to Buy at Fearnley; PT 172 kroner (+)
* OCI Raised to Buy at HSBC; PT 5.50 euros
* Witted Megacorp Raised to Buy at Inderes; PT 1.80 euros

>>> Down
* 2020 Bulkers Cut to Neutral at Clarksons; PT 148 kroner (+)
* A2A Cut to Neutral at Banca Akros (++)
* Biohit Cut to Reduce at Inderes; PT 3.70 euros
* Deutsche Post Cut to Equal-Weight at Morgan Stanley; PT 47 euros
* DSM-Firmenich Cut to Equal-Weight at Barclays; PT 85 euros
* Marks Electrical Group Cut to Hold at Shore Capital; PT 50 pence
* Martela Cut to Sell at Inderes; PT 70 euro cents
* Opap Cut to Hold at Wood & Company; PT 20 euros
* SSE Cut to Sell at Citi; PT 1,997 pence (+)
* Vestas Cut to Hold at Berenberg; PT 160 kroner

>>> Initiation
* Aalberts Rated New Outperform at Bernstein; PT 38 euros
* AbbVie Rated New Sector Outperform at Scotiabank; PT $280
* Agfa-Gevaert Cut to Hold at KBC Securities (+)
* Amgen Rated New Sector Outperform at Scotiabank; PT $385
* Belimo Rated New Sell at Van Lanschot Kempen
* Bristol Myers Rated New Sector Perform at Scotiabank; PT $45
* CoreWeave Rated New Buy at Compass Point; PT $150
* DSV ADRs Rated New Overweight at Morgan Stanley; PT $130
* Esi Rated New Buy at Euroland Corporate; PT 2.50 euros (+)
* Geberit Rated New Sell at Van Lanschot Kempen
* Gilead Rated New Sector Outperform at Scotiabank; PT $140
* Intertek Rated New Add at Peel Hunt; PT 5,498 pence
* Johnson & Johnson Rated New Sector Outperform at Scotiabank
* Merck & Co Rated New Sector Outperform at Scotiabank; PT $105
* Pfizer Rated New Sector Outperform at Scotiabank; PT $30
* PolyPeptide Group Rated New Buy at Berenberg; PT 30 Swiss francs
* Rea Holdings Rated New Speculative Buy at Canaccord (+)
* Regeneron Rated New Sector Perform at Scotiabank; PT $650
* Solaria Energia Cut to Neutral at CaixaBank BPI; PT 16.10 euros (++)

>>> Call
* Aalberts Outperform at Bernstein on Margin Expansion Potential
* Deutsche Bank Shares Have More Upside, JPMorgan Says (++)
* DSV Top Pick, DHL Cut as Morgan Stanley Selective in Transport
* Duerr Gains as Bernstein Highlights Significant Beat on Ebit (++)
* Givaudan Indicated Higher as Barclays Upgrades to Overweight (+)
*
* Siemens Falls as JPMorgan Notes FX Challenges, Opaque Guidance
* Vestas Downgraded at Berenberg With Better Outlook Now Priced In

>>> NIQ Global Intelligence plc misses by $0.03, beats on revs; guides Q4 revs

NIQ Global Intelligence plc misses by $0.03, beats on revs; guides Q4 revs above consensus; guides FY25 revs above consensus (14.25)
  • Reports Q3 (Sep) earnings of $0.03 per share, excluding non-recurring items, $0.03 worse than the FactSet Consensus of $0.06; revenues rose 7.2% year/year to $1.05 bln vs the $1.02 bln FactSet Consensus.
  • Co issues upside guidance for Q4, sees Q4 revs of $1.116-1.119 bln vs. $1.11 bln FactSet Consensus.
    • Q4 Adjusted EBITDA, as reported $277-281 mln
  • Co issues upside guidance for FY25, sees FY25 revs of $4.175-4.178 bln vs. $4.14 bln FactSet Consensus.
    • FY25 Adjusted EBITDA, as reported $905-909 mln

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • KRRO -76.4% (also provides updates on KRRO-110; also workforce reduction and resignation of Chief Medical Officer), ARDT -29.7%, WBTN -25.7% (also to develop slate of animated projects with Warner Bros. Animation), GAMB -19.3%, IBTA -18.8%, KLC -17%, PSFE -14.5%, ABSI -11.6%, DLO -11.2%, CCRN -9.5%, BITF -9.1%, EGAN -7%, HTFL -5.8%, ASND -5.6%, KDK -5.5%, ALVO -5.2%, ARMP -4.5%, NESR -4.5%, HZO -4.2%, DIS -3.5%, UAMY -3.3%, LB -2.5%, FLUT -2.3%, EPC -2.3%, SVCO -1.5%, AVR -1%, LAC -1%
Other news:
  • BTDR -15.8% ($400 mln convertible notes proposed private placement)
  • DAWN -13.9% (Day One Biopharmaceuticals (DAWN) to acquire Mersana Therapeutics for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to $30.25 per share)
  • CTEV -10.8% (prices offering by selling stockholders of 1.5 mln shares of common stock at $51.50 per share)
  • NFE -8.6% (to delay 10-Q filing)
  • ANNX -6.7% (prices $75 million public offering consisting of common stock and pre-funded warrants)
  • IVA -3.7% (files for $125 mln ADS offering)
  • NGNE -3.5% (interim data in pediatric cohort from NGN-401 gene therapy trial)
  • CTRI -2.8% (launches $160 mln stock offering; Icahn Partners to purchase $75 mln of shares in concurrent private placement)
  • IONS -2.8% (prices $700 mln convertible notes to refinance 2026 debt)
  • NKTR -2.2% (files mixed securities shelf offering)
  • INGM -1.3% (25.5 mln share offering by selling shareholders)
  • ALTS -0.9% (to delay 10-Q filing)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • FLY +21%, KRMD +18.5%, CLBT +17.8%, CURI +14.1%, CSIQ +11.8%, DGII +10.9%, CSCO +7.2%, AENT +6.9%, TATT +6%, NICE +5.9%, NOA +5.6%, NIQ +5.2%, DDS +4%, BILI +3.3%, ARX +3.2%, KEP +3%, GRAL +2.9%, SBET +2.6%, PAAS +2.4% (also increases dividend), TTEK +2.4% (also increases dividend), SBH +2.2%, SA +1.9%, NP +1.7%, ALH +1.6%, JD +1.4%, CELC +1.2%
Other news:
  • MRSN +202.4% (Day One Biopharmaceuticals (DAWN) to acquire Mersana Therapeutics for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to $30.25 per share)
  • SEE +21.5% (buyout firm in talks to take co private, according to WSJ)
  • ENGN +3.7% (prices $130 mln offering consisting of common shares and pre-funded warrants)
  • BWAY +2.7% (receives FDA clearance of Deep TMS as adjunct therapy for major depressive disorder in adolescents aged 15 to 21)
  • ATEX +2.6% (ATEX launches utility tower access product with CCI)
  • ELME +2.2% (completes sale of 19 multifamily communities for $1.6 Billion)
  • TFPM +1.3% (receives approval for normal course issuer bid renewal)
  • MHO +0.9% (authorizes new $250 mln share repurchase program)
  • ENVA +0.9% (authorizes new $400 mln share repurchase program)

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • MRSN +205.7%, FLY +25.9%, SEE +20.5%, KRMD +18.5%, CLBT +17.4%, CURI +14.9%, CSIQ +12.1%, NICE +7%, AENT +6.9%, CSCO +6.7%, TATT +6%, NOA +5.6%, ARX +5.2%, DGII +4.5%, KEP +4.5%, SBET +3.5%, ATEX +2.6%, BWAY +2.3%, RILY +2.1%, LFMD +1.9%, PAAS +1.9%, NP +1.7%, IVA +1.5%, BILI +1.5%, TFPM +1.3%, ENGN +1.2%, TTEK +1%
  • Gapping down:
    • KRRO -78.6%, ARDT -29.5%, WBTN -25.7%, ARMP -19.3%, IBTA -17.5%, KLC -16.8%, BTDR -15.6%, ABSI -12.1%, CCRN -11.1%, DLO -11%, NFE -9.5%, ALVO -8.4%, CTEV -8.3%, KDK -8.1%, EPC -7.5%, EGAN -7.4%, HTFL -5.8%, ANNX -4.9%, ASND -4.8%, NGNE -3.5%, DAWN -3.4%, IONS -2.8%, UAMY -2.2%, NKTR -2%, JOBY -1.7%, SVCO -1.5%, ALTS -1.4%, FLUT -1.4%, CTRI -1.3%, INGM -1.3%, FAST -1%

>>> Europe : Brokers Upgrades & Downgrades - 13th of November 2025 V2(+)

>>> Up
* ABN Amro GDRs PT Raised to 34 euros from 29 euros at RBC
* ABN Amro GDRs PT Raised to 34 euros from 29 euros at RBC
* Alcon AG Raised to Buy at Nephron Research
* Equinor Raised to Buy at SB1 Markets; PT 280 kroner
* FinecoBank PT Raised to 25.50 euros from 17 euros at Berenberg
* Givaudan Raised to Overweight at Barclays; PT 3,900 Swiss francs
* Kuehne + Nagel Raised to Equal-Weight at Morgan Stanley
* Matvareexpressen Raised to Hold at Norne Securities
* Torm Raised to Buy at Fearnley; PT 172 kroner (+)
* OCI Raised to Buy at HSBC; PT 5.50 euros
* Witted Megacorp Raised to Buy at Inderes; PT 1.80 euros

>>> Down
* 2020 Bulkers Cut to Neutral at Clarksons; PT 148 kroner (+)
* Biohit Cut to Reduce at Inderes; PT 3.70 euros
* Deutsche Post Cut to Equal-Weight at Morgan Stanley; PT 47 euros
* DSM-Firmenich Cut to Equal-Weight at Barclays; PT 85 euros
* Marks Electrical Group Cut to Hold at Shore Capital; PT 50 pence
* Martela Cut to Sell at Inderes; PT 70 euro cents
* Opap Cut to Hold at Wood & Company; PT 20 euros
* SSE Cut to Sell at Citi; PT 1,997 pence (+)
* Vestas Cut to Hold at Berenberg; PT 160 kroner

>>> Initiation
* Aalberts Rated New Outperform at Bernstein; PT 38 euros
* AbbVie Rated New Sector Outperform at Scotiabank; PT $280
* Agfa-Gevaert Cut to Hold at KBC Securities (+)
* Amgen Rated New Sector Outperform at Scotiabank; PT $385
* Belimo Rated New Sell at Van Lanschot Kempen
* Bristol Myers Rated New Sector Perform at Scotiabank; PT $45
* CoreWeave Rated New Buy at Compass Point; PT $150
* DSV ADRs Rated New Overweight at Morgan Stanley; PT $130
* Esi Rated New Buy at Euroland Corporate; PT 2.50 euros (+)
* Geberit Rated New Sell at Van Lanschot Kempen
* Gilead Rated New Sector Outperform at Scotiabank; PT $140
* Intertek Rated New Add at Peel Hunt; PT 5,498 pence
* Johnson & Johnson Rated New Sector Outperform at Scotiabank
* Merck & Co Rated New Sector Outperform at Scotiabank; PT $105
* Pfizer Rated New Sector Outperform at Scotiabank; PT $30
* PolyPeptide Group Rated New Buy at Berenberg; PT 30 Swiss francs
* Rea Holdings Rated New Speculative Buy at Canaccord (+)
* Regeneron Rated New Sector Perform at Scotiabank; PT $650

>>> Call
* Aalberts Outperform at Bernstein on Margin Expansion Potential
* DSV Top Pick, DHL Cut as Morgan Stanley Selective in Transport
* Givaudan Indicated Higher as Barclays Upgrades to Overweight (+)
* Siemens Falls as JPMorgan Notes FX Challenges, Opaque Guidance
* Vestas Downgraded at Berenberg With Better Outlook Now Priced In